David Huss, PhD, VP, Head of Research for Shape Therapeutics discusses the company's proprietary RNA technologies and how they will be applied to fix MECP2 mutations, the root cause of Rett syndrome.
David Huss, PhD, VP, Head of Research for Shape Therapeutics discusses the company's proprietary RNA technologies and how they will be applied to fix MECP2 mutations, the root cause of Rett syndrome.